Systemic treatments for hepatocellular carcinoma: challenges and future perspectives

Systemic treatments for hepatocellular carcinoma: challenges and future perspectives

Sorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, th...

Full description

Bibliographic Details
Main Authors: Francesco Tovoli, Giulia Negrini, Francesca Benevento, Chiara Faggiano, Elisabetta Goio, Alessandro Granito
Format: Article
Language:English
Published: Taylor & Francis 2018-01-01
Series:Hepatic Oncology
Subjects:
cabozantinib
hepatocellular carcinoma
immunotherapy
lenvatinib
metronomic capecitabine
regorafenib
Online Access:https://www.futuremedicine.com/doi/10.2217/hep-2017-0020

Internet

https://www.futuremedicine.com/doi/10.2217/hep-2017-0020

Similar Items